Southfield Capital, a private equity firm that focuses its investments in lower middle market companies, agreed to sell BioPharm Communications to Omnicom Health Group. The transaction is set to be completed in the second quarter of this year.
GREENWICH, CT – Southfield Capital, a leading lower middle market private equity firm, announced today that it has executed a Purchase Agreement to sell BioPharm Communications (“BioPharm”) to Omnicom Health Group. BioPharm is a leading communications agency that specializes in proprietary, multichannel marketing programs to physicians and healthcare practitioners for pharmaceutical and biotechnology clients.
The acquirer, Omnicom Health Group, is the largest healthcare marketing and communications group in the world, and part of Omnicom Group Inc. (NYSE: OMC).
The transaction is subject to regulatory approval and is expected to close in the second quarter of 2016.
Founded in New Hope, PA in 2005, BioPharm Communications (www.biopharmcommunications.com) helps brand teams at pharmaceutical and biotech companies execute customized marketing campaigns through a comprehensive portfolio of proprietary program offerings. As part of a customized 360º strategy, BioPharm educates healthcare professionals through the Peer-to-Peer360º suite, differentiates and builds brand awareness through the brand360° campaign approach, and tracks engagement instantly via the Insights360° CRM platform.
About Southfield Capital
Southfield Capital is a private equity firm that invests in exceptional, growing companies in the lower middle market. The firm makes control investments in North American companies generating $4 – 12 million in EBITDA with proven business models, attractive growth and profitability trends, and strong leadership. For more information, please visitwww.southfieldcapital.com.